MP
NUTX

Mangrove Partners’s Nutex Health NUTX Stock Holding History

Mangrove Partners’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,564
Closed -$422K – 545
2025
Q4 		$422K Buy
+2,564
New +$340K 0.03% 176

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

Mangrove Partners's NUTX Position: Q1 2026 in Review

Mangrove Partners sold out of Nutex Health (NUTX) in Q1 2026, closing a stake of 2,564 shares — an estimated $422K sold.

Mangrove Partners first reported a position in NUTX in Q4 2025 and held it in 1 quarter. The position peaked at $422K in Q4 2025. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • Mangrove Partners reported no remaining Nutex Health position as of Q1 2026 after selling out during the quarter.
  • Mangrove Partners sold 2,564 Nutex Health shares in Q1 2026, an estimated $422K.
  • Mangrove Partners first reported a position in Nutex Health in Q4 2025 and held it in 1 quarter.
  • Mangrove Partners's Nutex Health position peaked at $422K in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.